08:00 , Jan 6, 2014 |  BioCentury  |  Finance

4Q Stock Wrap-Up: All's well that ends well

Although two segments lost ground in 4Q13, all of biotech's market cap groups finished 2013 in the black. Large caps valued at more than $5 billion led the way in the fourth quarter, tacking on...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Clinical News

BindRen colestilan regulatory update

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that BindRen colestilan from Mitsubishi Tanabe has "no additional benefit" vs. sevelamer or calcium- or aluminum-containing phosphate binders to treat hyperphosphatemia in patients with...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
01:20 , Oct 2, 2013 |  BC Extra  |  Company News

G-BA rebuffs BindRen

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that BindRen colestilan from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) has "no additional benefit" vs. sevelamer or calcium- or aluminum-containing phosphate binders to treat...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

BindRen colestilan regulatory update

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that BindRen colestilan from Mitsubishi is worse than sevelamer to treat hyperphosphatemia in patients with stage 5 chronic kidney disease...
00:35 , Jul 2, 2013 |  BC Extra  |  Company News

IQWiG rebuffs BindRen

Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said in a preliminary benefit assessment that BindRen colestilan from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) is worse than sevelamer to treat hyperphosphatemia in patients with...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Company News

Mitsubishi Tanabe Pharma sales and marketing update

Mitsubishi's Mitsubishi Pharma Deutschland GmbH subsidiary launched BindRen colestilan in Germany and Austria to treat hyperphosphatemia in adult patients with stage 5 chronic kidney disease (CKD) receiving hemodialysis or peritoneal dialysis. Mitsubishi said in Germany...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Clinical News

BindRen colestilan regulatory update

The European Commission approved BindRen colestilan from Mitsubishi's Mitsubishi Pharma Europe Ltd. subsidiary to treat hyperphosphatemia in adult patients with stage 5 chronic kidney disease (CKD) receiving hemodialysis or peritoneal dialysis. The product is a...
08:00 , Feb 12, 2007 |  BioCentury  |  Strategy

Outward bound

Outward bound Outward boundWhile neither Mitsubishi nor Tanabe has any marketing presence in the U.S., and Mitsubishi has only a limited marketing presence in Europe, the newco will have retained worldwide rights to a number...